Q-omics provides the consensus-scored ZNF43 profile across patient tissues and cancer cell-line models. ZNF43 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZNF43 is differentially expressed in 12, with the highest sampling consensus in BRCA. Additionally, ZNF43 RNA expression shows 20,539 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, BRCA, and UVM as cancer lineages where ZNF43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF43 survival associations across molecular data types. ZNF43 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF43 RNA expression–survival associations across cancer types. High ZNF43 expression shows unfavorable associations in UVM, but favorable associations in LUAD, HNSC, MESO, BRCA and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZNF43 RNA expression.
This table summarizes ZNF43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF43 shows lower tumor expression in HNSC, LUSC and COAD and higher tumor expression in BRCA, LIHC and KIRC. The BRCA box plot shows higher ZNF43 RNA expression in tumor versus normal tissue (log2 FC = +0.795, t-test p < 0.001).
This table shows molecular features associated with ZNF43 in patient tissues and cancer cell lines. In patient samples, ZNF43 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
